Area of research
Infectious Diseases · Modeling and Simulation
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, COVID-19 epidemiological studies, and Vaccine Coverage and Hesitancy.
Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron
Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in Qatar
Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study
Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Duration of immune protection of SARS-CoV-2 natural infection against reinfection
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections
Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar
Estimated economic burden of genital herpes and HIV attributable to herpes simplex virus type 2 infections in 90 low- and middle-income countries: A modeling study
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar
Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic
Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar
Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses
SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar
Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020
Vulnerability of Syrian refugees in Lebanon to COVID-19: quantitative insights
Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950–2050
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting